Canagliflozin
FDA-approved product (tablet, oral), marketed as Canagliflozin, Invokana.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Diabetes mellitus
- Type 2 diabetes mellitus
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Sodium-glucose co-transporter 2 (sglt2) inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA54.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae21.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis45.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Canagliflozin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)
NCT01787357 · start 2008-06
Registered record
- Registry ID
- NCT01787357
- Conditions
- Healthy
- Interventions
- Canagliflozin (JNJ-28431754); Placebo; Moxifloxacin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-06
- Completion
- 2008-09
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionCanagliflozin (JNJ-28431754); Placebo; MoxifloxacinPhasePhase 1Registry statusCompletedA Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus
NCT01177163 · start 2008-05
Registered record
- Registry ID
- NCT01177163
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo; JNJ 28431754 300 mg/placebo; JNJ 28431754 100 mg/placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-05
- Completion
- 2009-03
- Enrolment
- 29
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetes Mellitus, Type 2InterventionPlacebo; JNJ 28431754 300 mg/placebo; JNJ 28431754 100 mg/placeboPhasePhase 1Registry statusCompletedA Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers
NCT01756417 · start 2007-10
Registered record
- Registry ID
- NCT01756417
- Conditions
- Healthy
- Interventions
- Metformin; Canagliflozin (JNJ-28431754)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2007-10
- Completion
- 2007-11
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionMetformin; Canagliflozin (JNJ-28431754)PhasePhase 1Registry statusCompletedA Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus
NCT00963768 · start 2007-06
Registered record
- Registry ID
- NCT00963768
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- JNJ 28431754; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2007-06
- Completion
- 2007-12
- Enrolment
- 116
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetes Mellitus, Type 2InterventionJNJ 28431754; PlaceboPhasePhase 1Registry statusCompletedA First-in-Human Study of JNJ-28431754 in Healthy Male Volunteers
NCT01177150 · start 2006-11
Registered record
- Registry ID
- NCT01177150
- Conditions
- Healthy
- Interventions
- JNJ-28431754/ Placebo; JNJ-28431754
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2006-11
- Completion
- 2007-04
- Enrolment
- 71
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionJNJ-28431754/ Placebo; JNJ-28431754PhasePhase 1Registry statusCompleted